Drug intelligence / Profile preview

EMP 116

Development stage: Preclinical
Lead developer: Empiriko
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMP 116 is an experimental PSMA-targeted radio-chemotherapy dual therapeutic being developed by Empiriko for the treatment of prostate cancer. The agent consists of a tumor-specific antibody conjugated to both a Lutetium-177 (177Lu) radiometal and a chemotherapy payload via a modified RCV-Chemo-Ab complex. This dual-modality approach is designed to deliver targeted ionizing radiation and cytotoxic chemotherapy simultaneously to PSMA-expressing tumor cells, potentially overcoming resistance mechanisms associated with monotherapies and improving clinical outcomes in prostate cancer patients.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on EMP 116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP 116.

Explore the full profile